Generic drugmaker Mylan NV has recalled about 81,000 EpiPen devices in countries outside the United States, following two reports of the life-saving allergy shot failing to work in emergencies.
In both situations, patients were able to obtain treatment through the use of an alternate EpiPen, Mylan said on Wednesday.
The recall affects devices distributed in Australia, New Zealand, Europe and Japan only, according to the company.
